Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 9, 2003. The report details a share repurchase transaction and provides a statement regarding the launch of a generic version of paroxetine hydrochloride in the United States.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The only specific financial data disclosed relates to a share buyback:
- Shares Repurchased: 790,000 ordinary shares.
- Repurchase Date: September 8, 2003.
- Price per Share: 1,265.66p.
- Purpose: Cancellation of shares under authority granted at the May 19, 2003 Annual General Meeting.
Material Changes and Operational Updates
The primary material event reported is the launch of a generic paroxetine hydrochloride by Apotex Corp. on September 8, 2003. This event triggered a license agreement between GSK and Par Pharmaceutical, Inc., under which GSK will supply generic immediate-release tablets for distribution in the U.S. market. GSK notes that its extended-release product, Paxil CR, now represents approximately 40% of new Paxil prescriptions in the USA and is not substitutable by the generic immediate-release forms.
Outlook, Risks, and Contingencies
GSK is actively pursuing litigation regarding patent infringement for the immediate-release form of Paxil against Apotex and other generic companies in Philadelphia; no trial date has been set. Additionally, GSK is appealing a March 2003 ruling by a federal judge in Chicago which found GSK's patent covering the hemihydrate form of Paxil valid but not infringed by Apotex's product. The patent in question expires in 2006. No hearing date for the appeal has been set.
Investor Verification Checklist
- Verify the total cost of the 790,000 share repurchase and its impact on cash reserves.
- Monitor the status of the Philadelphia litigation regarding immediate-release Paxil patent infringement.
- Track the progress of the appeal regarding the Chicago ruling on the hemihydrate form patent.
- Assess the market share trajectory of Paxil CR versus generic immediate-release products in the U.S.
- Confirm the terms and financial implications of the supply agreement with Par Pharmaceutical, Inc.